Chief Executive Officer, Scintilla Pharmaceuticals, Inc.
Jaisim Shah currently serves as the Chief Executive Officer and board member of Scintilla Pharmaceuticals and is a board member of Sorrento Therapeutics, Inc. He was CEO, Co-founder and President of Semnur Pharmaceuticals, Inc. from 2013 until 2016. Prior to Semnur, Jaisim was a consultant to several businesses, including his current role as board member of Sorrento Therapeutics, Inc. From 2011 through 2012, Jaisim was the chief business officer of Elevation Pharmaceuticals where he led the sale of it to Sunovion/DSP Pharmaceuticals. Prior to Elevation, Jaisim was president of Zelos Therapeutics, and previously was the SVP and chief business officer at CytRx.
From 2000 to 2009, Jaisim was chief business officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/ partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka and Biogen Idec. His leadership in marketing and commercial enterprise helped the company make large improvements to meet its profitability potential. Prior to PDL, from 1997 to 2000, he was at Bristol-Myers Squibb, most recently as Vice President of Global and US Marketing for Neuroscience and Infectious Disease Franchises where he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history with the Otsuka Abilify Collaboration. Previously from 1991 to 1997, Jaisim was at F. Hoffmann-La Roche in management positions in oncology and virology and was global business leader, which included managing corporate alliances with Genentech and Idec. Jaisim led international marketing for oncology and virology and prepared products for worldwide launch and pre-launch at F. Hoffman-LaRoche AG in Switzerland. He has played a key role in the formulation of long-range plans and pre-launch and launch strategies for such brands as Abilify®, Pegasys® and Rituxan/MabThera®, each of which have generated well over $1 billion in sales. Jaisim holds an MA in Economics from the University of Akron and an MBA from University of Oklahoma.